TherOx AO System (Now Zoll)

Close-up view of the TherOx AO System showing the user interface, control knobs and equipment housing.
Case Studies

Therox AO System (Now Zoll)

Client Snapshot
Sector: Surgical

Client Snapshot

TherOx AO System

Current standard of care for the most severe heart attacks involves mechanically opening the blocked artery using percutaneous coronary intervention (PCI), otherwise known as angioplasty and stenting.

Rendered image of the TherOx AO System showing the complete oxygenation unit on a wheeled base with integrated controls.

While PCI has reduced early mortality post-heart attack over the past 25 years, significant myocardial tissue (heart muscle) death and sizable scarring may be present even after the left anterior descending (LAD) artery has been stented. This myocardial damage is linked to increased risk of heart failure and long-term mortality2.

SSO2 Therapy is a novel treatment that complements PCI and is designed to minimize myocardial damage caused by acute myocardial infarction in qualifying patients suffering a LAD ST-elevation myocardial infarction (STEMI) event who are treated with primary PCI within 6 hours of symptom onset. SSO2 Therapy delivers superoxygenated arterial blood directly to at-risk myocardial tissue and is performed in the cardiac catheterization laboratory immediately after PCI is completed.

Side view of the TherOx AO oxygenation system showing the treatment chamber, tubing connections and control interface.
Full view of the TherOx AO System positioned next to a technician height reference, showing device scale and configuration.
Three TherOx AO System units in different color schemes displayed side by side to show design variations and configuration options.